
Agilon Health (AGL) Stock Forecast & Price Target
Agilon Health (AGL) Analyst Ratings
Bulls say
Agilon Health is viewed positively because repeated quarterly beats and guidance raises point to a business that is improving faster than expected, driven by favorable risk adjustment, better payer contracting, stronger ACO performance, and tighter control of medical costs. Revenue of $1.49 billion to $1.52 billion was up 6% to 7% year over year, while medical margins of 11.5% and $197 million materially exceeded guidance, and FY26 AEBITDA guidance rose from $30 million or $85 million to as high as $145 million-$155 million. The outlook is further supported by expansion in high-risk patient management programs, lower estimated cost trends at 5.8%, and solid financial flexibility with $257 million in cash and only $32 million of debt, positioning FY27 for further margin expansion and cash positivity.
Bears say
Agilon Health is exposed to a fragile operating model because its growth depends on identifying and developing successful new markets while also relying heavily on payors for membership attribution, reporting accuracy, claims payments, and risk adjustment factors that determine reimbursement. This creates meaningful execution risk, as any disruption in payor data quality or reimbursement mechanics could quickly pressure margins and make it harder to achieve and maintain profitability. In addition, competition and ongoing industry consolidation may intensify pricing pressure and limit the company’s ability to scale efficiently, reinforcing a negative fundamental outlook.
This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Agilon Health (AGL) Forecast
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares